{"entity":{"id":"nct06178159","kind":"trial","name":"DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer","aka":[],"tldr":"A phase 2 trial of Disitamab vedotin, Pertuzumab and Toripalimab in HER2-positive breast cancer, run by RemeGen Co., Ltd., now recruiting.","summary":"DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer is a phase 2 interventional study registered as NCT06178159 by RemeGen Co., Ltd., with 40 participants planned, started 2023-11-28 and due to reach its primary completion in 2026-06. Interventions recorded: Disitamab Vedotin Injection, Pertuzumab Injection and Toripalimab.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06178159","url":"https://clinicaltrials.gov/study/NCT06178159"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-her2-positive","her2-positive-early-breast-cancer"],"sections":[],"technologies":["adc","checkpoint-inhibitor","monoclonal-antibody"],"targets":[],"drugs":["disitamab-vedotin","pertuzumab","toripalimab"],"companies":["remegen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06178159","phase":"2","setting":"A Phase II, Multicenter, Open-Label Neoadjuvant Study to Evaluate the Safety and Efficacy of Disitamab Vedotin in Combination With Pertuzumab With or Without Toripalimab for HER2 Positive Breast Cancer","sponsor":"RemeGen Co., Ltd.","started":"2023-11-28","startedType":"actual","enrolled":40,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06178159/","neighbours":{"cancer":[{"id":"her2-positive-early-breast-cancer","kind":"cancer","name":"Early HER2-positive breast cancer","route":"/cancers/her2-positive-early-breast-cancer/"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"disitamab-vedotin","kind":"drug","name":"Disitamab vedotin","route":"/drugs/disitamab-vedotin/"},{"id":"pertuzumab","kind":"drug","name":"Pertuzumab","route":"/drugs/pertuzumab/"},{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/"}],"company":[{"id":"remegen","kind":"company","name":"RemeGen","route":"/companies/remegen/"}]}}